Heat shock protein 90 (HSP90) is overexpressed in p16-negative oropharyngeal squamous cell carcinoma, and its inhibition in vitro potentiates the effects of chemoradiation

Cancer Chemotherapy and Pharmacology

Volumn 74, Issue 5, 2014, Pages 1015-1022

  Patel, Kirtesh ^a   Wen, Jing ^a   Magliocca, Kelly ^a   Muller, Susan ^a   Liu, Yuan ^b   Chen, Zhuo Georgia ^a   Saba, Nabil ^a   Diaz, Roberto ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b EMORY UNIVERSITY   (United States)

Author keywords

Cisplatin; Ganetespib; Head neck cancer; HPV; HSP90; Radiation therapy

Indexed keywords

CISPLATIN; DEFEROXAMINE; GANETESPIB; HEAT SHOCK PROTEIN 90; PROTEIN P16; ANTINEOPLASTIC AGENT; CYCLIN DEPENDENT KINASE INHIBITOR 2A; HYPOXIA INDUCIBLE FACTOR 1ALPHA; TRIAZOLE DERIVATIVE;

APOPTOSIS; ARTICLE; CANCER TISSUE; CAUCASIAN; CELL VIABILITY; CHEMORADIOTHERAPY; COMPARATIVE STUDY; CONTROLLED STUDY; DNA DAMAGE; DRUG EFFICACY; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; OROPHARYNX CARCINOMA; OROPHARYNX SQUAMOUS CELL CARCINOMA; SQUAMOUS CELL CARCINOMA; WART VIRUS; WESTERN BLOTTING; ANTAGONISTS AND INHIBITORS; CELL HYPOXIA; CELL PROLIFERATION; CELL SURVIVAL; DOSE RESPONSE; DRUG EFFECTS; FEMALE; MALE; METABOLISM; OROPHARYNX TUMOR; PAPILLOMA VIRUS; PATHOLOGY; PHYSIOLOGY; RADIATION RESPONSE; TUMOR CELL LINE; VIROLOGY;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; CARCINOMA, SQUAMOUS CELL; CELL HYPOXIA; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CISPLATIN; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DEFEROXAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOSE-RESPONSE RELATIONSHIP, RADIATION; FEMALE; HSP90 HEAT-SHOCK PROTEINS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; IMMUNOHISTOCHEMISTRY; MALE; OROPHARYNGEAL NEOPLASMS; PAPILLOMAVIRIDAE; TRIAZOLES;

EID: 84919951690     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-014-2584-8     Document Type: Article

References (23)

1. Cancer Facts & Figures (2012) American Cancer Society (ACS) (2012). J Consum Health Internet 16(3):366-367
2. Pignon JP, Bourhis J, Domenge C, Designe L (2000) Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-analysis of chemotherapy on head and neck cancer. Lancet 355(9208):949-955
3. Forastiere AA, Zhang Q, Weber RS, Maor MH, Goepfert H, Pajak TF, Morrison W, Glisson B, Trotti A, Ridge JA, Thorstad W, Wagner H, Ensley JF, Cooper JS (2013) Long-term results of RTOG 91-11: a comparison of three nonsurgical treatment strategies to preserve the larynx in patients with locally advanced larynx cancer. J Clin Oncol 31(7):845-852. doi: 10.1200/JCO.2012.43.6097
4. Leemans CR, Braakhuis BJ, Brakenhoff RH (2011) The molecular biology of head and neck cancer. Nat Rev Cancer 11(1):9-22. doi: 10.1038/nrc2982
5. Ang KK, Harris J, Wheeler R, Weber R, Rosenthal DI, Nguyen-Tan PF, Westra WH, Chung CH, Jordan RC, Lu C, Kim H, Axelrod R, Silverman CC, Redmond KP, Gillison ML (2010) Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 363(1):24-35. doi: 10.1056/NEJMoa0912217
6. Gillison ML, D'Souza G, Westra W, Sugar E, Xiao W, Begum S, Viscidi R (2008) Distinct risk factor profiles for human papillomavirus type 16-positive and human papillomavirus type 16-negative head and neck cancers. J Natl Cancer Inst 100(6):407-420. doi: 10.1093/jnci/djn025
7. Westra WH, Taube JM, Poeta ML, Begum S, Sidransky D, Koch WM (2008) Inverse relationship between human papillomavirus-16 infection and disruptive p53 gene mutations in squamous cell carcinoma of the head and neck. Clin Cancer Res 14(2):366-369. doi: 10.1158/1078-0432.CCR-07-1402
8. Lassen P, Eriksen JG, Hamilton-Dutoit S, Tramm T, Alsner J, Overgaard J, Danish H, Neck Cancer G (2010) HPV-associated p16-expression and response to hypoxic modification of radiotherapy in head and neck cancer. Radiother Oncol 94(1):30-35. doi: 10.1016/j.radonc.2009.10.008
9. Rischin D, Young RJ, Fisher R, Fox SB, Le QT, Peters LJ, Solomon B, Choi J, O'Sullivan B, Kenny LM, McArthur GA (2010) Prognostic significance of p16INK4A and human papillomavirus in patients with oropharyngeal cancer treated on TROG 02.02 phase III trial. J Clin Oncol 28(27):4142-4148. doi: 10.1200/JCO.2010.29.2904
10. Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, Jones CU, Sur R, Raben D, Jassem J, Ove R, Kies MS, Baselga J, Youssoufian H, Amellal N, Rowinsky EK, Ang KK (2006) Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354(6):567-578. doi: 10.1056/NEJMoa053422
11. Wegele H, Muller L, Buchner J (2004) Hsp70 and Hsp90-a relay team for protein folding. Rev Physiol Biochem Pharmacol 151:1-44. doi: 10.1007/s10254-003-0021-1
12. Whitesell L, Lindquist SL (2005) HSP90 and the chaperoning of cancer. Nat Rev Cancer 5(10):761-772. doi: 10.1038/nrc1716
13. Koukourakis MI, Giatromanolaki A, Sivridis E, Simopoulos C, Turley H, Talks K, Gatter KC, Harris AL (2002) Hypoxia-inducible factor (HIF1A and HIF2A), angiogenesis, and chemoradiotherapy outcome of squamous cell head-and-neck cancer. Int J Radiat Oncol Biol Phys 53(5):1192-1202
14. Ang KK, Berkey BA, Tu X, Zhang HZ, Katz R, Hammond EH, Fu KK, Milas L (2002) Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res 62(24):7350-7356
15. Goldman JW, Raju RN, Gordon GA, El-Hariry I, Teofilivici F, Vukovic VM, Bradley R, Karol MD, Chen Y, Guo W, Inoue T, Rosen LS (2013) A first in human, safety, pharmacokinetics, and clinical activity phase I study of once weekly administration of the Hsp90 inhibitor ganetespib (STA-9090) in patients with solid malignancies. BMC Cancer 13:152. doi: 10.1186/1471-2407-13-152
16. Kimple RJ, Smith MA, Blitzer GC, Torres AD, Martin JA, Yang RZ, Peet CR, Lorenz LD, Nickel KP, Klingelhutz AJ, Lambert PF, Harari PM (2013) Enhanced radiation sensitivity in HPV-positive head and neck cancer. Cancer Res 73(15):4791-4800. doi: 10.1158/0008-5472.Can-13-0587
17. Zhao M, Sano D, Pickering CR, Jasser SA, Henderson YC, Clayman GL, Sturgis EM, Ow TJ, Lotan R, Carey TE, Sacks PG, Grandis JR, Sidransky D, Heldin NE, Myers JN (2011) Assembly and initial characterization of a panel of 85 genomically validated cell lines from diverse head and neck tumor sites. Clin Cancer Res 17(23):7248-7264. doi: 10.1158/1078-0432.CCR-11-0690
18. Kumar B, Cordell KG, Lee JS, Worden FP, Prince ME, Tran HH, Wolf GT, Urba SG, Chepeha DB, Teknos TN, Eisbruch A, Tsien CI, Taylor JM, D'Silva NJ, Yang K, Kurnit DM, Bauer JA, Bradford CR, Carey TE (2008) EGFR, p16, HPV Titer, Bcl-xL and p53, sex, and smoking as indicators of response to therapy and survival in oropharyngeal cancer. J Clin Oncol 26(19):3128-3137. doi: 10.1200/JCO.2007.12.7662
19. Castle PE, Ashfaq R, Ansari F, Muller CY (2005) Immunohistochemical evaluation of heat shock proteins in normal and preinvasive lesions of the cervix. Cancer Lett 229(2):245-252. doi: 10.1016/j.canlet.2005.06.045
20. Chung CH, Zhang Q, Kong C, Harris J, Ang KK, Harari PM, Wang D, Redmond KP, Shenouda G, Trotti A, Raben D, Gillison ML, Jordan R, Le QT (2013) p16 expression as a human papillomavirus (HPV)-independent prognostic biomarker in non-oropharyngeal squamous cell carcinoma (non-OPSCC). J Clin Oncol 31(15-suppl):6007
21. Poeta ML, Manola J, Goldwasser MA, Forastiere A, Benoit N, Califano JA, Ridge JA, Goodwin J, Kenady D, Saunders J, Westra W, Sidransky D, Koch WM (2007) TP53 mutations and survival in squamous-cell carcinoma of the head and neck. N Engl J Med 357(25):2552-2561. doi: 10.1056/NEJMoa073770
22. Brand TM, Iida M, Wheeler DL (2011) Molecular mechanisms of resistance to the EGFR monoclonal antibody cetuximab. Cancer Biol Ther 11(9):777-792. doi: 10.4161/cbt.11.9.15050
23. Skinner HD, Sandulache VC, Ow TJ, Meyn RE, Yordy JS, Beadle BM, Fitzgerald AL, Giri U, Ang KK, Myers JN (2012) TP53 disruptive mutations lead to head and neck cancer treatment failure through inhibition of radiation-induced senescence. Clin Cancer Res 18(1):290-300. doi: 10.1158/1078-0432.CCR-11-2260